The literature‐based evidence posits that IL‐6 acts as an early sensor of injury,[57] while IL‐17A is directly involved in immune cell recruitment and inflammatory lung pathology.[58, 59] Moreover, our findings provide preliminary support for the application of existing inhibitors targeting IL‐6 and IL‐17A for VOCs‐induced lung disease. This evidence concerns the gene IL6 and lung disorder.